Company · founded 1965

Charles River Associates

Boston, United States · charlesriverassociates.com

Manage this page

Citations, last 5 years: 680
Works, last 5 years: 184
h-index: 83
Scientists listed: 13
Grants since 2016: 1 402

Grants received

2016–2026 · training · T32

Advanced Research Training in Communication Sciences and Disorders

Cara E. Stepp · Charles River Associates · funded by National Institutes of Health

$337.6k

2016–2026 · research · R35

Analysis and Prediction of Molecular Interactions

Sandor Vajda · Charles River Associates · funded by National Institutes of Health

$546.2k

2016–2026 · research · R35

Chemical Synthesis of Complex Natural Products for Translational Science

John A. Porco · Charles River Associates · funded by National Institutes of Health

$25.7k

2016–2027 · research · R35

MODELING EMERGENT BEHAVIORS IN SYSTEMS BIOLOGY: A BIOLOGICAL PHYSICS APPROACH

Pankaj Mehta · Charles River Associates · funded by National Institutes of Health

$396k

2016–2026 · research · R01

Spatial Hearing in Speech Mixtures

Virginia Ann Best · Charles River Associates · funded by National Institutes of Health

$412.5k

2015–2022 · research · R01

Global mapping and analysis of a bacterial transcriptional regulatory network

James E Galagan · Charles River Associates · funded by National Institutes of Health

$452.9kBacterial Genetics and Biotechnology

2015–2024 · research · R01

Sensing Vulnerable Plaque in vivo by an All-optical Intravascular Ultrasound and Photoacoustic Catheter

Ji-Xin Cheng · Charles River Associates · funded by National Institutes of Health

$612.5kPhotoacoustic and Ultrasonic Imaging

2015–2020 · research · R01

In Vivo Photoactoustic Sensing of Lipid Laden Plaque

Ji-Xin Cheng · Charles River Associates · funded by National Institutes of Health

$588.4kPhotoacoustic and Ultrasonic Imaging

2015–2024 · research · R01

Sensing Vulnerable Plaque in vivo by an All-optical Intravascular Ultrasound and Photoacoustic Catheter

Ji-Xin Cheng · Charles River Associates · funded by National Institutes of Health

$580.4kPhotoacoustic and Ultrasonic Imaging

2015–2023 · research · R01

Probing the roles of membrane and cholesterol on Aβ biogenesis and prion protein interactions

John E. Straub · Charles River Associates · funded by National Institutes of Health

$379.4kAlzheimer's disease research and treatments

2015–2020 · research · R25

An open, online course in neuronal data analysis for the practicing neuroscientist

Uri Tzvi Eden · Charles River Associates · funded by National Institutes of Health

$171.4kUndergraduate Neuroscience Education and Research

2015–2020 · cooperative agreement · UC4

Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes management

Roy W. Beck · Charles River Associates · funded by National Institutes of Health

$1.5MDiabetes Management and Research

2015–2023 · research · R01

Probing the roles of membrane and cholesterol on Aβ biogenesis and prion protein interactions

John E. Straub · Charles River Associates · funded by National Institutes of Health

$379.4kAlzheimer's disease research and treatments

2015–2024 · research · R01

Sensing Vulnerable Plaque in vivo by an All-optical Intravascular Ultrasound and Photoacoustic Catheter

Ji-Xin Cheng · Charles River Associates · funded by National Institutes of Health

$634.5kPhotoacoustic and Ultrasonic Imaging

2015–2025 · research · R01

Sensing Vulnerable Plaque in vivo by an All-optical Intravascular Ultrasound and Photoacoustic Catheter

Ji-Xin Cheng · Charles River Associates · funded by National Institutes of Health

$589.6kPhotoacoustic and Ultrasonic Imaging

2015–2024 · research · R01

Probing the roles of membrane and cholesterol on Aβ biogenesis and prion protein interactions

John E. Straub · Charles River Associates · funded by National Institutes of Health

$379.4kAlzheimer's disease research and treatments

2015–2023 · research · R01

Probing the roles of membrane and cholesterol on Aβ biogenesis and prion protein interactions

John E. Straub · Charles River Associates · funded by National Institutes of Health

$395.6kAlzheimer's disease research and treatments

2015–2020 · career development · K23

Isolating Mechanisms in the Treatment of Borderline Personality Disorder

Shannon E Sauer-Zavala · Charles River Associates · funded by National Institutes of Health

$168kPersonality Disorders and Psychopathology

2015–2021 · research · R01

Rapid molecular diagnostic for chlamydia and gonorrhea at the point-of-care

Catherine M. Klapperich · Charles River Associates · funded by National Institutes of Health

$409.4kReproductive tract infections research

2014–2024 · research · R01

Top-Down Control of Selective Amplification

Gerald Kidd · Charles River Associates · funded by National Institutes of Health

$654.3k

2014–2025 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$472k

2014–2020 · research · R01

Organization of Excitatory and Inhibitory Circuits in ASD

Vasileios Zikopoulos · Charles River Associates · funded by National Institutes of Health

$409.3kAutism Spectrum Disorder Research

2014–2024 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$412.2k

2014–2024 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$412.2k

2014–2025 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$77.8k

2014–2025 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$472k

2014–2026 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$77.8k

2014–2025 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$472k

2014–2025 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$412.2k

2014–2024 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$412.2k

2014–2024 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$428.5k

2014–2024 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$41.5k

2014–2025 · research · R01

Cell-to-cell heterogeneity and the emergence of antibiotic resistance

Mary Dunlop · Charles River Associates · funded by National Institutes of Health

$50.2k

2014–2024 · research · R01

Top-Down Control of Selective Amplification

Gerald Kidd · Charles River Associates · funded by National Institutes of Health

$654.3k

2014–2024 · research · R01

Top-Down Control of Selective Amplification

Gerald Kidd · Charles River Associates · funded by National Institutes of Health

$654.3k

2014–2025 · research · R01

Top-Down Control of Selective Amplification

Virginia Ann Best · Charles River Associates · funded by National Institutes of Health

$647.3k

2014–2025 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$472k

2014–2026 · research · R01

Xenobiotic-responsive hepatic long non-coding RNAs

David J Waxman · Charles River Associates · funded by National Institutes of Health

$472k

2014–2020 · research · R01

Epigenetic Actions of Environmental Chemicals

David J Waxman · Charles River Associates · funded by National Institutes of Health

$403.9k

2014–2024 · research · R01

Top-Down Control of Selective Amplification

Gerald Kidd · Charles River Associates · funded by National Institutes of Health

$683.1k